BTIG Healthcare Investment Banking Adds Mikhail Keyserman, CMT, CFTe, as Managing Director to Bolster Biotechnology Client Resources

NEW YORK--(BUSINESS WIRE)--BTIG announced today that Mikhail Keyserman, CMT, CFTe, has transitioned into the firm’s Healthcare Investment Banking division. In his new role as a Managing Director and biotechnology specialist, he will focus on identifying investment banking and capital markets opportunities across the biotech industry. Mr. Keyserman will be based out of the firm’s New York office and report directly to K.C. Stone, Managing Director, Head of BTIG Healthcare Investment Banking.

Healthcare Investment Banking continues to be a key area of focus at BTIG. The firm has experienced a notable increase in healthcare deal flow and has a very active pipeline of transactions to execute on behalf of private and public companies in 2022.

“Since joining the firm, Mikhail has leveraged his extensive relationships with corporate leadership teams and institutional investors across the capital markets spectrum to drive adoption of our healthcare platform,” commented Matt Clark, Managing Director, Head of BTIG Investment Banking. “We are very excited about the energy and expertise that Mikhail will bring to our healthcare banking practice and look forward to his contributions.”

Prior to his new role with the firm, Mr. Keyserman served as a Managing Director and Senior Healthcare Strategy and Franchise Sales Specialist at BTIG. As part of BTIG’s Franchise Sales unit, he focused on building relationships with CIOs, portfolio managers, and analysts, delivering actionable trading ideas, promoting the firm’s corporate access program and generating healthcare sales commentary. Mr. Keyserman has 15 years of industry experience across a number of healthcare-focused investment and trading roles. Prior to BTIG, he was a Partner at Nexthera Capital. Previously, Mr. Keyserman was the Head Trader at Millennium Partners. He also held equity research, healthcare sector specialist and trading roles at Leerink Partners and Citi.

“I have worked closely with Mikhail in his role as Senior Healthcare Strategy and Franchise Sales Specialist at the firm and believe that his biotech expertise will be highly accretive to our practice,” commented Mr. Stone.

BTIG Investment Banking’s expertise spans the consumer, energy and infrastructure, financials, healthcare, real estate as well as technology, media and telecommunications sectors. The firm’s banking products include mergers and acquisitions, capital markets advisory, IPOs, follow-on offerings, ATMs, SPACs, private placements, convertibles, debt and corporate buybacks. Clients benefit from actionable market intelligence, and BTIG’s comprehensive understanding of financial dynamics. Aftermarket services include trading, corporate access, as well as proprietary research and strategy products.

About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 19 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.

Disclaimer: https://www.btig.com/disclaimer. To learn more about BTIG, visit www.btig.com.